Trelegy Formulation
Trelegy Ellipta is a once-daily, single-inhaler triple therapy delivered as a dry powder inhaler containing fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta-2 agonist). 1
Device and Delivery System
The medication is delivered through the ELLIPTA inhaler, a light grey and beige plastic device containing 2 separate foil blister strips 1:
- First blister strip: Contains micronized fluticasone furoate (100 or 200 mcg) mixed with lactose monohydrate
- Second blister strip: Contains micronized umeclidinium bromide (74.2 mcg equivalent to 62.5 mcg umeclidinium) and micronized vilanterol trifenatate (40 mcg equivalent to 25 mcg vilanterol), plus magnesium stearate and lactose monohydrate
When activated, both blisters simultaneously expose their powder contents for inhalation through the mouthpiece 1.
Available Strengths
Two formulations are available 1:
- FF/UMEC/VI 100/62.5/25 mcg (approved for COPD and asthma)
- FF/UMEC/VI 200/62.5/25 mcg (approved for asthma)
Actual Delivered Dose
Under standardized testing conditions at 60 L/min flow rate, the inhaler delivers 1:
- 92 or 184 mcg of fluticasone furoate
- 55 mcg of umeclidinium
- 22 mcg of vilanterol
The device maintains ≥90% of target dose delivery across flow rates of 30-90 L/min, making it effective even in patients with severe airflow limitation 1.
Clinical Context
This single-inhaler formulation represents an advancement over multiple-inhaler regimens, as it combines all three medication classes in one device with once-daily dosing 2. The ELLIPTA device has demonstrated good adherence and patient preference in real-world studies 3, with mean peak inspiratory flows of 65.8 L/min in very severe COPD patients and 96.6 L/min in severe asthma patients 1.
Important caveat: The lactose monohydrate excipient contains milk proteins, which is relevant for patients with severe milk protein allergy 1.